Plasma Protease C1-inhibitor Treatment Industry by Applications, Region, Type and Top Players Analysis up to 2025

on

01th November 2018: This Report Studies the Global Plasma Protease C1-inhibitor Treatment Market size, industry status and forecast, competition landscape and growth opportunity. This Research Report categorizes the Global Plasma Protease C1-inhibitor Treatment Industry by Companies, Region, Application, Type and end-use Industry.
Global Plasma Protease C1-inhibitor Treatment market is expected to grow at the highest CAGR in the upcoming years. C1-inhibitor is also known as C1-INH and C1 esterase inhibitor. C1-INH’s deficiency is the genetic defect underlying hereditary angioedema (HAE). Plasma protease C1-inhibitor concentrate is an effective and safe treatment for acute hereditary angioedema (HAE) attacks. The factors that play an important role in the growth of plasma protease C1-inhibitor treatment industry are prevalence of rare diseases, novel therapies, promising pipeline drugs, increasing investments in innovation of inhibitor drugs, and rising awareness regarding HAE.
Growth drivers for the plasma protease C1-inhibitor treatment market are rising practice of administering prophylactic treatment process for hereditary angioedema (HAE) patients, increasing demand for administering drugs internally among HAE patients, and new route for highly demand of C1-inhibitor drugs. This market is segmented on the basis of drug class, dosage type, distribution channel, and geography.
Based on drug class, the plasma protease C1-inhibitor treatment industry is classified as C1-inhibitors, kallikrein inhibitor (kalbitor), selective bradykinin B2 receptor antagonist (firazyr) and so on. The segment “C1-inhibitor” is sub-divided into C1-esterase inhibitor, recombinant inhibitor, and so on. Also, this segment held the highest market share in the past few years as C1-inhibitor drugs are usually used for the treatment of acute hereditary angioedema (HAE) and prophylaxis. Based on dosage type, the plasma protease C1-inhibitor treatment market is classified as liquid/injectable, lyophilized, and so on. The segment “lyophilized” held highest share in the past few years due to rising practice of intravenous administration of drugs for the treatment of HAE.
Based on distribution channel, the plasma protease C1-inhibitor treatment industry is classified as hospital pharmacies, independent pharmacies & outlets, and so on. Based on geography, the plasma protease C1-inhibitor treatment industry is classified as North America (U.S., Canada), Latin America (Brazil, Argentina, and Rest of Latin America), Europe (EU-5 Countries, BENELUX countries, Rest of Europe), and Rest of World (Israel, Australia, Rest of world countries).
Latin America and Asia Pacific are expected to control the lyophilized segment positively due to growth in high demand for intravenous C1 esterase inhibitor drugs market. Key players operating in the plasma protease C1-inhibitor treatment market are Shire plc, Sanquin, CSL Limited, Vertec Biosolvents, Somaiya Group, Pharming Group N.V., Yancheng Hongtai Bioengineering and Huade Biological Engineering.

Comments

Post a Comment